{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:14:41Z","timestamp":1788869681649,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,1,19]],"date-time":"2012-01-19T00:00:00Z","timestamp":1326931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s12350-011-9508-3","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T19:51:35Z","timestamp":1326916295000},"page":"319-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Karthik","family":"Ananthasubramaniam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"McNutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Klauke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Feaheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Bukofzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-011-9508-3_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0002-9149(97)00256-7","article-title":"Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology","volume":"79","author":"Shryock","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-011-9508-3_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0031-6997(24)01511-4","article-title":"International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol Rev"},{"key":"10.1007\/s12350-011-9508-3_bib3","doi-asserted-by":"crossref","first-page":"33D","DOI":"10.1016\/j.amjcard.2004.04.017","article-title":"The future of pharmacologic stress: Selective A2A adenosine receptor agonists","volume":"94","author":"Cerqueira","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1007\/s12350-011-9508-3_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1081\/NCN-100002306","article-title":"2-substituted pi system derivatives of adenosine that are coronary vasodilators acting via the A2A adenosine receptor","volume":"20","author":"Zablocki","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1007\/s12350-011-9508-3_bib5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0022-3565(24)29370-8","article-title":"Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: Inverse relationship between affinity and duration of action of A2A agonists","volume":"298","author":"Gao","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s12350-011-9508-3_bib6","unstructured":"Lexiscan\u00ae (regadenoson injection) [prescribing information]. Deerfield, IL: Astellas Pharma US Inc. April 2011."},{"key":"10.1007\/s12350-011-9508-3_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/VHRM.S1798","article-title":"Regadenoson in the detection of coronary artery disease","volume":"4","author":"Buhr","year":"2008","journal-title":"J Vasc Health Risk Manag"},{"key":"10.1007\/s12350-011-9508-3_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/RMI.S3978","article-title":"Update on myocardial perfusion imaging: Role of regadenoson","volume":"2","author":"Hendel","year":"2009","journal-title":"Rep Med Imaging"},{"key":"10.1007\/s12350-011-9508-3_bib9","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2009.04.089","article-title":"Regadenoson: A new myocardial stress agent","volume":"54","author":"Al Jaroudi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-011-9508-3_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/10489040-000000000-00000","article-title":"Regadenoson","volume":"10","author":"Garnock-Jones","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1007\/s12350-011-9508-3_bib11","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2146\/news080078","article-title":"FDA approves pharmacologic stress agent","volume":"65","author":"Thompson","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1007\/s12350-011-9508-3_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0091270007301620","article-title":"Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function","volume":"47","author":"Gordi","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1007\/s12350-011-9508-3_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00006231-200606000-00009","article-title":"Myocardial perfusion imaging in the elderly: A review","volume":"27","author":"De Winter","year":"2006","journal-title":"Nucl Med Commun"},{"key":"10.1007\/s12350-011-9508-3_bib14","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/sj.ki.5002374","article-title":"Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study","volume":"72","author":"Wetzels","year":"2007","journal-title":"Kidney Int"},{"key":"10.1007\/s12350-011-9508-3_bib15","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1053\/j.ajkd.2009.09.035","article-title":"Prevalence of CKD and comorbid illness in elderly patients in the United States: Results from the Kidney Early Evaluation Program (KEEP)","volume":"55","author":"Stevens","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1007\/s12350-011-9508-3_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/HJH.0b013e328332038c","article-title":"Chronic kidney disease in hypertension under specialist care: The I-DEMAND study","volume":"28","author":"Leoncini","year":"2010","journal-title":"J Hypertens"},{"key":"10.1007\/s12350-011-9508-3_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nuclcard.2007.06.114","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-011-9508-3_bib18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","article-title":"Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging","volume":"1","author":"Cerqueira","year":"2008","journal-title":"J Am Coll Cardiol Imaging"},{"key":"10.1007\/s12350-011-9508-3_bib19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1007\/s12350-011-9508-3_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1007\/s12350-011-9508-3_bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1007\/s12350-011-9508-3_bib22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.2165\/00003088-200645120-00005","article-title":"A population pharmacokinetic\/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers","volume":"45","author":"Gordi","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1007\/s12350-011-9508-3_bib23","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1056\/NEJMoa043104","article-title":"Obstructive sleep apnea as a risk factor for stroke and death","volume":"353","author":"Yaggi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1007\/s12350-011-9508-3_bib24","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.jacc.2005.05.097","article-title":"Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging","volume":"46","author":"Hendel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s12350-011-9508-3_bib25","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nuclcard.2007.02.016","article-title":"Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans","volume":"14","author":"Lieu","year":"2007","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-011-9508-3_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.105.095323","article-title":"Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats","volume":"316","author":"Dhalla","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s12350-011-9508-3_bib27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/clpt.2008.208","article-title":"Assessment of the impact of renal impairment on systemic exposure of new molecular entities: Evaluation of recent new drug applications","volume":"85","author":"Zhang","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1007\/s12350-011-9508-3_bib28","first-page":"658","article-title":"Frequency of aminophylline use to attenuate adverse reactions to regadenoson and adenosine","volume":"16","author":"Cerqueira","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-011-9508-3_bib29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2967\/jnmt.109.065581","article-title":"Advances in pharmacologic stress agents: Focus on regadenoson","volume":"38","author":"Johnson","year":"2010","journal-title":"J Nucl Med Technol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-011-9508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12350-011-9508-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123030891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123030891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12350-011-9508-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-011-9508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T05:53:06Z","timestamp":1761025986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123030891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S1071358123030891"],"URL":"https:\/\/doi.org\/10.1007\/s12350-011-9508-3","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-011-9508-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}